Raymond James Financial
KYTX icon

Raymond James Financial’s Kyverna Therapeutics KYTX Stock Holding History

Raymond James Financial’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$139K Sell
16,082
-9,000
-36% -$75K ﹤0.01% 4964
2025
Q4 		$236K Buy
+25,082
New +$186K ﹤0.01% 4709
2025
Q3 		– Sell
-189
Closed -$580 – 6854
2025
Q2 		$580 Buy
+189
New +$467 ﹤0.01% 6656

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Raymond James Financial's KYTX Position: Q1 2026 in Review

Raymond James Financial reduced its Kyverna Therapeutics (KYTX) stake by 36% in Q1 2026, selling an estimated $75K and leaving 16,082 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #4964.

Raymond James Financial first reported a position in KYTX in Q2 2025 and has held it in 3 quarters since. The position peaked at $236K in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Raymond James Financial held 16,082 shares of Kyverna Therapeutics worth $139K as of Q1 2026.
  • Raymond James Financial sold 9,000 Kyverna Therapeutics shares in Q1 2026, an estimated $75K.
  • Kyverna Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4964 holding.
  • Raymond James Financial first reported a position in Kyverna Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Raymond James Financial's Kyverna Therapeutics position peaked at $236K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.